Bradley Foster & Sargent’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.69M Sell
17,635
-451
-2% -$69.1K 0.04% 194
2025
Q4
$2.49M Sell
18,086
-226
-1% -$29.6K 0.04% 197
2025
Q3
$2.35M Sell
18,312
-2,643
-13% -$323K 0.03% 205
2025
Q2
$2.54M Sell
20,955
-6,003
-22% -$677K 0.04% 199
2025
Q1
$3.01M Sell
26,958
-1,800
-6% -$192K 0.05% 175
2024
Q4
$2.8M Sell
28,758
-125
-0.4% -$13.3K 0.05% 182
2024
Q3
$3.32M Sell
28,883
-495
-2% -$56.2K 0.06% 170
2024
Q2
$3.13M Sell
29,378
-419
-1% -$42.1K 0.06% 171
2024
Q1
$2.88M Sell
29,797
-2,570
-8% -$263K 0.05% 176
2023
Q4
$3.27M Sell
32,367
-5,062
-14% -$489K 0.06% 171
2023
Q3
$3.78M Hold
37,429
0.08% 160
2023
Q2
$3.78M Sell
37,429
-250
-0.7% -$25K 0.08% 160
2023
Q1
$3.47M Sell
37,679
-432
-1% -$37.7K 0.08% 154
2022
Q4
$3.46M Sell
38,111
-1,242
-3% -$105K 0.09% 142
2022
Q3
$2.99M Sell
39,353
-965
-2% -$80K 0.08% 152
2022
Q2
$3.41M Sell
40,318
-1,475
-4% -$129K 0.09% 143
2022
Q1
$3.67M Sell
41,793
-3,309
-7% -$286K 0.08% 156
2021
Q4
$3.94M Sell
45,102
-6,894
-13% -$572K 0.08% 150
2021
Q3
$4.25M Sell
51,996
-9,648
-16% -$868K 0.1% 128
2021
Q2
$5.62M Sell
61,644
-76,977
-56% -$6.85M 0.13% 115
2021
Q1
$11.8M Sell
138,621
-33,817
-20% -$3.03M 0.3% 76
2020
Q4
$16.3M Sell
172,438
-1,055
-0.6% -$92.2K 0.43% 64
2020
Q3
$15.1M Buy
+173,493
New +$15M 0.44% 59
2020
Q1
$15.5M Buy
187,829
+1,760
+0.9% +$157K 0.62% 47
2019
Q4
$17.6M Sell
186,069
-9,184
-5% -$824K 0.54% 55
2019
Q3
$17M Buy
195,253
+7,250
+4% +$651K 0.57% 56
2019
Q2
$17.2M Sell
188,003
-3,997
-2% -$338K 0.57% 58
2019
Q1
$16.5M Buy
192,000
+3,514
+2% +$282K 0.58% 58
2018
Q4
$14.5M Sell
188,486
-4,413
-2% -$344K 0.59% 57
2018
Q3
$14.9M Sell
192,899
-10,999
-5% -$813K 0.51% 62
2018
Q2
$13.8M Sell
203,898
-3,759
-2% -$259K 0.49% 62
2018
Q1
$15M Sell
207,657
-1,401
-0.7% -$107K 0.57% 57
2017
Q4
$15.7M Sell
209,058
-2,791
-1% -$211K 0.57% 60
2017
Q3
$16.3M Sell
211,849
-2,480
-1% -$187K 0.62% 59
2017
Q2
$16M Sell
214,329
-7,547
-3% -$535K 0.64% 54
2017
Q1
$14.8M Sell
221,876
-88,016
-28% -$5.87M 0.6% 58
2016
Q4
$20.2M Sell
309,892
-255,690
-45% -$16.6M 0.86% 39
2016
Q3
$40M Sell
565,582
-3,928
-0.7% -$286K 1.75% 13
2016
Q2
$42.1M Sell
569,510
-12,158
-2% -$840K 1.89% 12
2016
Q1
$37.8M Buy
581,668
+15,458
+3% +$1.05M 1.75% 14
2015
Q4
$43.7M Buy
566,210
+5,230
+0.9% +$415K 2% 12
2015
Q3
$46.2M Buy
560,980
+8,833
+2% +$786K 2.28% 7
2015
Q2
$48.7M Buy
552,147
+4,979
+0.9% +$457K 2.22% 6
2015
Q1
$48.3M Buy
547,168
+31,971
+6% +$2.84M 2.2% 5
2014
Q4
$42.8M Buy
515,197
+641
+0.1% +$53.1K 2.01% 8
2014
Q3
$43.4M Sell
514,556
-10,458
-2% -$846K 2.06% 6
2014
Q2
$42.6M Sell
525,014
-8,037
-2% -$632K 2.07% 6
2014
Q1
$40.6M Buy
533,051
+15,324
+3% +$1.12M 2.11% 5
2013
Q4
$37.3M Buy
517,727
+4,767
+0.9% +$331K 1.98% 5
2013
Q3
$35.3M Buy
512,960
+7,681
+2% +$508K 2.06% 5
2013
Q2
$32M Buy
+505,279
New +$32.9M 1.98% 8

Other funds holding NVS

Bradley Foster & Sargent's NVS Position: Q1 2026 in Review

Bradley Foster & Sargent reduced its Novartis (NVS) stake by 2.5% in Q1 2026, selling an estimated $69.1K and leaving 17,635 shares worth $2.69M. The position accounts for 0.04% of the portfolio, ranked #194.

Bradley Foster & Sargent first reported a position in NVS in Q2 2013 and has held it in 51 quarters since. The position peaked at $48.7M in Q2 2015. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Bradley Foster & Sargent held 17,635 shares of Novartis worth $2.69M as of Q1 2026.
  • Bradley Foster & Sargent sold 451 Novartis shares in Q1 2026, an estimated $69.1K.
  • Novartis made up 0.04% of Bradley Foster & Sargent's portfolio in Q1 2026, its #194 holding.
  • Bradley Foster & Sargent first reported a position in Novartis in Q2 2013 and has held it in 51 quarters since.
  • Bradley Foster & Sargent's Novartis position peaked at $48.7M in Q2 2015.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Bradley Foster & Sargent's 13F filing for Q1 2026, filed 15 May 2026.